EVGN — Evogene Ltd.

Summary of Evogene's Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenues: Total revenues for 2025 were approximately $3.9 million, down from $5.6 million in 2024. Q4 2025 revenues were approximately $0.3 million, a decrease from $1.5 million in Q4 2024.
• Operating Expenses: Operating expenses decreased significantly to about $13.8 million for 2025, down from $22 million in 2024. Q4 operating expenses were approximately $3.2 million compared to $4.3 million in Q4 2024.
• Net Loss: The net loss for 2025 was approximately $7.8 million, a substantial decrease from $18.1 million in 2024. Q4 2025 net loss was approximately $5.4 million, compared to a minimal loss of $5,000 in Q4 2024.
• Cash Position: As of December 31, 2025, Evogene held approximately $13 million in cash, with a cash usage of about $3 million in Q4 2025.

2. Strategic Updates and Business Highlights

• Refocused Strategy: Evogene has streamlined its operations to concentrate on two key markets: human health (small molecule drugs) and agriculture (novel ag chemicals) using its ChemPass AI platform.
• ChemPass AI: The AI engine is designed to generate novel, highly active molecules while meeting complex parameters to enhance development success. Collaborations with Google Cloud have advanced the platform's capabilities.
• Partnerships: Evogene is actively pursuing partnerships in drug discovery and ag chemicals, with multiple collaborations already in progress and expectations for further scaling in 2026.

3. Forward Guidance and Outlook

• Cash Sufficiency: Management indicated that the cash from Lavie Bio and Biomica, along with existing resources, should sustain operations for at least 1.5 years without additional financing.
• Catalysts: Expected catalysts include new technology collaborations, additional pharma and biotech partnerships, and potential agreements with chemical companies, which could inject cash into the company.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The decrease in revenues, particularly from AgPlenus and Casterra, raises concerns about market demand and operational performance.
• Impairment Losses: Casterra recorded a $2.2 million inventory impairment due to operational ceasing in Kenya, reflecting challenges in the agricultural segment.
• Operational Adjustments: Significant downsizing in Biomica and Lavie Bio indicates a strategic shift that may impact future growth prospects in those areas.

5. Notable Q&A Insights

• BMC128 License Agreement: The agreement with Lishan Pharmaceuticals includes milestone payments and revenue sharing, which could be significant for Evogene.
• Future Cash Flow: Management expects cash distributions from Lavie Bio and Biomica to support operations, with a focus on securing additional collaborations to enhance financial stability.
• Strategic Focus: Ofer Haviv emphasized the commitment to the core business strategy and the potential for innovation in collaboration with major tech and chemical companies, highlighting a shift away from legacy activities.

Overall, Evogene is positioning itself for long-term growth through strategic focus and innovation, despite facing challenges in revenue generation and operational adjustments.